Activin ligand-trap biological therapy

Phase 2Small molecule

Activin ligand-trap biological therapy is one of 27 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart Failure With Preserved Ejection FractionRecruiting

Heart FailurePhase 2

Active, not recruiting

Heart Failure With Preserved Ejection FractionPhase 2

Recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Zemplar

AbbVie

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Zoloft

VViatris Specialty LLC

Preclinical

2 7

Xifaxan

SSalix

Preclinical

2 8

Activin ligand-trap biological therapy

MMassachusetts General Hospital

Phase 2

1 9

Coumadin

AAbbott

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Heart Failure With Preserved Ejection Fraction

NCT07202000

Clinical

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction1 trial

Double-blind, Prospective, Randomized, Placebo-controlled Trial to Assess if Activin Ligand-trap Biological Therapy Can Improve Exercise Capacity and Cognitive Function in Heart Failure With Preserved Ejection Fraction Compared to Placebo.

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07202000·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Activin ligand-trap biological therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Activin ligand-trap biological therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Activin ligand-trap biological therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

Activin ligand-trap biological therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News